<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30093976</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>55</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>17</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.</ArticleTitle>            <Pagination>                <MedlinePgn>30649-30660</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25769</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Developing multiple cancers is an indicator of underlying hereditary cancer predisposition, but there is a paucity of data regarding the clinical genetic testing outcomes of these patients.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We compared cancer index patients with ≥2 primary malignancies versus 1 primary cancer who underwent clinical evaluation and testing with multi-gene panels comprising up to 49 genes from 1998-2016.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among 1191 cancer index patients, 80.6%, 17.2%, and 2.2% respectively had 1, 2, and ≥3 primary malignancies. For patients with 2 primary cancers (n=205), the most common cancer pairs were bilateral breast (37.5%), breast-ovary (11.7%), endometrium-ovary (9.2%), colon-endometrium (3.9%) and colon-colon (3.4%). 42.3% patients underwent gene testing including 110/231 (47.6%) with multiple malignancies. Pathogenic variants were found more frequently in younger patients, in those with a family history of cancer related to the suspected syndrome, and a trend towards significance in those with multiple primary cancers (35.5% vs. 25.6%, p = 0.09). In patients with multiple cancers, pathogenic variants were most commonly identified in BRCA1 (38.5%), BRCA2 (17.9%), and the mismatch repair genes (20.5%), while 23.1% of pathogenic mutations were in other moderate- to high-penetrance cancer predisposition genes including APC, ATM, MUTYH, PALB2, RAD50 and TP53.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Patients with multiple cancers were more likely to carry pathogenic mutations than those with single cancer. About three-quarters of deleterious mutations in patients with multiple primary cancers were in BRCA1/2 and the mismatch repair genes, but multi-gene panel testing facilitated the detection of mutations in another 6 genes and is warranted in this high-risk population.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chan</LastName>                    <ForeName>Gloria H J</ForeName>                    <Initials>GHJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ong</LastName>                    <ForeName>Pei Yi</ForeName>                    <Initials>PY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Low</LastName>                    <ForeName>Jeffrey J H</ForeName>                    <Initials>JJH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynaecology, National University Hospital, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kong</LastName>                    <ForeName>Hwai Loong</ForeName>                    <Initials>HL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ow</LastName>                    <ForeName>Samuel G W</ForeName>                    <Initials>SGW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tan</LastName>                    <ForeName>David S P</ForeName>                    <Initials>DSP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Science Institute, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Yi Wan</ForeName>                    <Initials>YW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Siew Eng</ForeName>                    <Initials>SE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Soo-Chin</ForeName>                    <Initials>SC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Science Institute, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Genet. 2014 Sep;86(3):229-37</RefSource>                <PMID Version="1">24304220</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 May 1;34(13):1460-8</RefSource>                <PMID Version="1">26976419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2017 Sep 1;3(9):1190-1196</RefSource>                <PMID Version="1">28418444</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genet Med. 2016 Aug;18(8):823-32</RefSource>                <PMID Version="1">26681312</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Hum Genet. 2015 May;23(5):581-7</RefSource>                <PMID Version="1">25248401</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2015 Apr;137(1):86-92</RefSource>                <PMID Version="1">25622547</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gastroenterology. 1999 Jun;116(6):1453-6</RefSource>                <PMID Version="1">10348829</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Feb 28;13(1):R20</RefSource>                <PMID Version="1">21356067</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Sep 10;27(26):e108-9; author reply e110</RefSource>                <PMID Version="1">19652052</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Acad Med Singapore. 2015 Oct;44(10):492-510</RefSource>                <PMID Version="1">26763067</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2016 Sep;13(9):581-8</RefSource>                <PMID Version="1">27296296</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Fam Cancer. 2014 Dec;13(4):527-36</RefSource>                <PMID Version="1">25117502</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gastroenterology. 2011 Jan;140(1):73-81</RefSource>                <PMID Version="1">20727894</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2017 Jan 1;140(1):95-102</RefSource>                <PMID Version="1">27616075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Surv. 1995;25:101-24</RefSource>                <PMID Version="1">8718514</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2017 Sep 29;12(9):e0185615</RefSource>                <PMID Version="1">28961279</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Jan;161(1):95-102</RefSource>                <PMID Version="1">27783279</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 1997 May 15;336(20):1409-15</RefSource>                <PMID Version="1">9145677</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2011 Nov 1;129(9):2256-62</RefSource>                <PMID Version="1">21171015</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med Genet. 2008 Dec 22;9:116</RefSource>                <PMID Version="1">19102775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62</RefSource>                <PMID Version="1">9392616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Genomics Hum Genet. 2017 Aug 31;18:201-227</RefSource>                <PMID Version="1">28504904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genet Test Mol Biomarkers. 2012 Jul;16(7):785-93</RefSource>                <PMID Version="1">22536849</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">genetic testing</Keyword>            <Keyword MajorTopicYN="N">germ-line mutation</Keyword>            <Keyword MajorTopicYN="N">multiple primary/diagnosis</Keyword>            <Keyword MajorTopicYN="N">neoplasms</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30093976</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25769</ArticleId>            <ArticleId IdType="pii">25769</ArticleId>            <ArticleId IdType="pmc">PMC6078133</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>